Neuroblastoma, Unspecified Childhood Solid Tumor, Excluding CNS
Conditions
Brief summary
RATIONALE: MLN8237 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of MLN8237 and to see how well it works in treating young patients with relapsed or refractory solid tumors
Detailed description
1.1 Primary Aims 1.1.1 To estimate the maximum tolerated dose (MTD) and recommended Phase II dose of MLN8237 administered orally once daily for 7 days every 21 days to children with refractory solid tumors. 1.1.2 To estimate the maximum tolerated dose (MTD) and recommended Phase II dose of MLN8237 administered orally twice daily for 7 days every 21 days to children with refractory solid tumors. 1.1.3 To define and describe the toxicities of MLN8237 administered on this schedule. 1.1.4 To characterize the pharmacokinetics of MLN8237 in children with refractory cancer. 1.2 Secondary Aims 1.2.1 To preliminarily define the antitumor activity of MLN8237 within the confines of a Phase I study. 1.2.2 To obtain initial Phase II efficacy data on the anti-tumor activity of MLN8237 in children with relapsed-refractory neuroblastoma using the once daily dosing schedule. 1.2.3 To explore the relationship between polymorphic variations in the UDPglucuronyltransferase gene UGT1A1 and exposure to MLN8237. 1.2.4 To assess two common polymorphic variants in the Aurora A kinase gene (Phe31Ile and Val57Ile) thought to potentially influence tumorigenesis. 1.2.5 To preliminarily examine the relationsh
Interventions
DRUGMLN8237
Sponsors
National Cancer Institute (NCI)
Children's Oncology Group
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Months to 21 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis: Patients must have had histologic verification of malignancy at original diagnosis or relapse except in patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of CSF or serum tumor markers including alpha-fetaprotein or beta-HCG. * Performance Level: Karnofsky \>/= 50% for patients \> 16 years of age and Lansky \>/= 50 for patients \</=16 years of age * Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study * Adequate Bone Marrow Function Defined as: a. For patients with solid tumors: * Peripheral absolute neutrophil count (ANC) \>/= 1000/microLiter * Platelet count \>/= 100,000/microLiter (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment) * Hemoglobin \>/= 8.0 g/dL (may receive RBC transfusions) * Creatinine clearance or radioisotope GFR \>/= 70ml/min/1.73 m2 * Bilirubin (sum of conjugated + unconjugated) \</= 1.5 x upper limit of normal (ULN) for age, and * SGPT (ALT) \</= 5.0 x ULN for age (≤ 225 U/L). For the purpose of this study, the ULN for SGPT is 45 U/L. * Serum albumin \>/= 2 g/dL.
Exclusion criteria
* Pregnant or breast-feeding women will not be entered on this study * Growth factors that support platelet or white cell number or function must not have been administered within the 7 days prior to enrollment. * Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the prior 7 days are not eligible. * Patients who are currently receiving another investigational drug are not eligible. * Patients who are currently receiving other anticancer agents, digoxin, cyclosporine, tacrolimus or sirolimus, use of daily benzodiazepines are not eligible * Patients who have an uncontrolled infection are not eligible.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine maximum tolerated dose and RP2D administered once daily on Days 1-7 | Up to 21 days (1st cycle) of protocol therapy | — |
| Determine maximum tolerated dose and RP2D administered po BID on Days 1-7 | Up to 21 days (1st cycle) of protocol therapy | — |
| Adverse events as assessed by (CTCAE) version 4.0 | Every 21 days (each cycle) of protocol therapy for up to 35 cycles [up to 105 weeks] | DLT will be defined as possibly, probably or definitely attributable to MLN8237. The DLT observation period for the purposes of dose-escalation will be the first cycle of therapy |
| PK Profile: MLN8237 concentrations in plasma samples | 30 min after the first dose, and at 1,2, 3, 4, 6-8, 24 hours, Day 4 and 7 in Cycle 1 | single-dose AUC, trough estimation, t½ of accumulation |
Outcome results
None listed